Notes
2009 values
Reference
Franken MG, et al. Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib? Value in Health 17: 245-53, No. 2, Mar 2014. Available from: URL: http://dx.doi.org/10.1016/j.jval.2013.12.009
Rights and permissions
About this article
Cite this article
Challenges of outcomes research provide lessons for policymakers. PharmacoEcon Outcomes News 700, 4 (2014). https://doi.org/10.1007/s40274-014-1160-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-014-1160-0